Invariant NKT cells are resistant to circulating CD15+ myeloid-derived suppressor cells in patients with head and neck cancer.
Bottom Line: However, the effect on the host immune system, especially on invariant NKT (iNKT) cells with potent anti-tumor activity, remains unclear.However, iNKT cell activation upon α-galactosylceramide (αGalCer) stimulation was not affected by the presence or absence of CD15+ G-MDSC.Cancer immunotherapy designed to enhance the antitumor activity of iNKT cells by stimulation with αGalCer may remain effective in the presence of G-MDSC.
Affiliation: Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.Show MeSH
Related in: MedlinePlus
Mentions: The association of tumor differentiation and clinical stage of HNSCC with the ratio of G‐MDSC, M‐MDSC and CD3+ cells in PBC before treatment were analyzed in a total of 32 patients with HNSCC. There were no significant differences in the percentage of G‐MDSC, M‐MDSC and CD3+ cell in the pathological differentiation (Table 2). The percentage of G‐MDSC was significantly higher in patients with advanced stage III/IV compared with those with stage I/II (Fig. 4b), but not in M‐MDSC (Fig. 4a). There were no significant differences in CD3+ cells between the clinical stages (Fig. 4c). The percentage of iNKT cells in HNSCC patients was not decreased compared with healthy donors (Fig. 4d). The overall survival rate in the HNSCC patients with increased M‐MDSC (>3%) were not significantly different compared with those of patients with normal numbers of M‐MDSC in all stages (Fig. 4e), stage III/IV (Fig. 4f) or stage IV (data not shown). However, the overall survival rate in HNSCC patients with increased G‐MDSC (>1%) was significantly lower compared with survival of patients with normal levels of G‐MDSC in all stages (Fig. 4g), stage III/IV (Fig. 4h) and stage IV (data not shown).
Affiliation: Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.